Method of reducing the cardiotoxic side effects of glycosidic anthracyclinones

Abstract

The cardiotoxic effects incident to the use of glycosidic anthracyclinones such as adriamycin, daunomycin, etc., in antitumor therapy, are substantially reduced by administering to a host undergoing such therapy, and effective amount of coenzymes Q, particularly Co-Q.sub.10 (Ubiquinone Q.sub.10).

Dependencies are inferred from the claim text.